# Assessing the Long-Term Impact of the COVID-19 Pandemic on Hospital Outcomes in Patients with Decompensated Liver Cirrhosis

**Authors:** Melania Veronica Ardelean, Ovidiu Florin Ardelean, Dana Roxana Buzas, Paul Ciubotaru, Vlad Ivan, Alin Viorel Istodor, Daniel Florin Lighezan, Norina Simona Basa

PMC · DOI: 10.3390/medicina62020404 · 2026-02-19

## TL;DR

The study shows that the COVID-19 pandemic worsened outcomes for patients with severe liver cirrhosis due to disrupted healthcare access and delayed treatments.

## Contribution

This study is the first to assess the long-term impact of the pandemic on cirrhosis patients across pre-, during, and post-pandemic periods.

## Key findings

- Mortality increased during the pandemic and remained elevated afterward.
- Access to endoscopic evaluations dropped significantly during the pandemic.
- Acute complications like jaundice and bleeding became major causes of death during the pandemic.

## Abstract

Background and Objectives: The COVID-19 pandemic profoundly disrupted global healthcare systems, limiting access to diagnostic and therapeutic services for chronic diseases. Patients with decompensated liver cirrhosis were particularly vulnerable due to their fragile clinical status and dependence on continuous medical care. This study aimed to evaluate the temporal evolution of clinical, biological, and prognostic parameters in patients admitted emergently with decompensated liver cirrhosis across three distinct phases: pre-pandemic, pandemic, and post-pandemic. Materials and Methods: A retrospective, single-center study was conducted at the Department of Gastroenterology, Municipal Clinical Emergency Hospital, Timișoara, Romania, including 355 patients hospitalized between February 2018 and February 2024. Clinical, biochemical, and outcome data were collected and analyzed using univariate and multivariate logistic regression models to identify independent predictors of in-hospital mortality for each study period. Results: Significant temporal variations were observed in disease severity, management, and outcomes. The mean MELD score increased from 18.7 to 21.0 during the pandemic (p = 0.043), while endoscopic evaluations declined markedly (59.4% pre-pandemic vs. 42.7% pandemic, p = 0.037). Mortality rose from 21.7% to 30.2% during the pandemic (p = 0.044) and remained elevated post-pandemic (26.4%). Multivariate regression identified Child–Pugh, MELD, and Baveno scores as consistent mortality predictors, though their relative weight varied by period. During the pandemic, acute complications—particularly jaundice (OR = 294) and upper gastrointestinal bleeding (OR = 355)—became dominant determinants of death. Conclusions: The pandemic transformed cirrhosis from a chronic, manageable disease into an acutely unstable condition, primarily due to delayed presentation and restricted procedural access. Although post-pandemic recovery was evident, residual increases in mortality and severity indicate lasting effects of healthcare disruption, underscoring the need to strengthen system resilience and continuity of care for patients with chronic liver disease.

## Linked entities

- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Diseases:** HCC (MESH:D006528), chronic diseases (MESH:D002908), post-COVID (MESH:D000094024), LGIB (MESH:D006471), hepatic decompensation (MESH:D006333), renal dysfunction (MESH:D007674), systemic (MESH:D015619), hepatic synthetic failure (MESH:D017093), Hepatic encephalopathy (MESH:D006501), hepatic injury (MESH:D056486), thrombocytopenia (MESH:D013921), COVID (MESH:D000086382), bacterial peritonitis (MESH:D010538), viral hepatitis B and C (MESH:D006525), Infection (MESH:D007239), congestion (MESH:D002311), cardiovascular, oncologic, and gastrointestinal conditions (MESH:D002318), acute-on-chronic liver failure (MESH:D065290), MELD (MESH:D058625), ascites (MESH:D001201), nosocomial infection (MESH:D003428), portal hypertension (MESH:D006975), viral infections (MESH:D014777), alcoholic cirrhosis (MESH:D008104), melena (MESH:D008551), Mortality (MESH:D003643), esophageal varices (MESH:D004932), non-alcoholic steatohepatitis (MESH:D005235), hemorrhagic (MESH:D006470), splenomegaly (MESH:D013163), hematemesis (MESH:D006396), Jaundice (MESH:D007565), LLE (MESH:D004487), hepatitis C (MESH:D019698), Decompensated Liver Cirrhosis (MESH:D008103), Abdominal pain (MESH:D015746), Cirrhosis (MESH:D005355), chronic hepatic insufficiency (MESH:D048550), variceal bleeding (MESH:D014648), injury to (MESH:D014947), chronic liver disease (MESH:D008107), inflammation (MESH:D007249), cirrhotic (MESH:D000094724)
- **Chemicals:** alcohol (MESH:D000438), creatinine (MESH:D003404), bilirubin (MESH:D001663)
- **Species:** Homo sapiens (human, species) [taxon 9606], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049]

---
Source: https://tomesphere.com/paper/PMC12942391